Clinical efficiency of desmopressin and cyclooxygenase inhibitor use in incontinent women

Cover Page

Abstract


Hypothesis/aims of study. Questions regarding the pathogenesis of urine incontinence and methods of treatment are acti vely discussed by gynecologists, urologists, and neuropathologists. Urine incontinence often has multifactor origins: the causes of urine incontinence are connected, as a rule, with the violation of urine continence functional mechanisms, anatomotopographical features of the lower urinary tract, or an premature ovarian failure. Simultaneously, changes in kidney function play a role in the pathogenesis of urine incontinence. In some cases, urine incontinence is combined with urine overproduction or inversion of the circadian rhythm of renal function owing to a decrease in the reabsorption of sodium ions in the thick ascending limb of the loop of Henle. In some patients, we successfully normalized ion transport, diuresis, and circadian rhythm of urine production by desmopressin or diclofenac administration. The present analysis was undertaken to evaluate the clinical efficiency of desmopressin and diclofenac in incontinent patients with nocturnal polyuria and polyuria.

Study design, materials, and methods. In total, 130 patients with complaints of urinary incontinence, polyuria (24-h urine volume of 40 mL/kg bodyweight or above), or nocturnal polyuria (nocturnal volume/24-h urine volume of 0.33 or above); 30 incontinent women without polyuria or nocturnal polyuria (comparison group); and 14 control subjects were included. The mean patient age was 43.6 ± 4.5 years (41.8 ± 3.7 years in the comparison group and 39.4 ± 6.3 years in the control group, p > 0.05). All the participants performed seven days of urine collection to determine the voided volumes. Patients with polyuria or nocturnal polyuria performed the 3-fold 24-h pad-test. Patients with polyuria and nocturnal polyuria were examined twice: in the initial state and one month after the start of treatment with the optimal dose of diclofenac or desmopressin (Minirin).

Results. The use of both diclofenac or desmopressin in patients with various types of urine incontinence, polyuria, or nocturia decreased the volume of voided urine because of the normalization of diuresis and an increase in cystometric bladder capacity.


Natalya A. Osipova

Author for correspondence.
naosipova@mail.ru
Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Russian Federation, St. Petersburg

Professor Assistant, PhD, Medical Faculty. Department of Obstetrics, Gynecology and Reproductology

Dariko A. Niauri

d.niauri@mail.ru
Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Russian Federation, St. Petersburg

MD, Prof. PhD, DMedSci, Medical Faculty, Department of Obstetrics, Gynecology and Reproductology

Alexander M. Gzgzyan

iagmail@ott.ru
Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Russian Federation, St. Petersburg

MD, PhD, DMedSci, Medical Faculty, Department of Obstetrics, Gynecology and Reproductology, Head of Reproductive Technologies Department

  • Аполихина И.А., Ромих В.В., Андикян В.М. Современные принципы консервативного лечения недержания мочи у женщин // Урология. — 2005. — № 5. — С. 72–75. [Apolikhina IA, Romikh VV, Andikyan VM. Current principles of conservative treatment of urine incontinence in women. Urologiia. 2005;(5):72-75. (In Russ.)]
  • Балан В.Е., Анкирская А.С., Есесидзе З.Т., Муравьева В.В. Патогенез атрофического цистоуретрита и различные виды недержания мочи у женщин в климактерии // Consilium medicum. — 2001. — Т. 3. — № 7. — С. 326–331. [Balan VE, Ankirskaya AS, Esesidze ZT, Murav’eva VV. Pathogenesis of atrophic cystourethritis and various types of urinary incontinence in women in menopause. Consilium medicum. 2001;3(7):326-331. (In Russ.)]
  • Неймарк А.И., Раздорская М.В. Актуальные проблемы урогинекологии. Недержание мочи у женщин (лекция) // Акушерство, гинекология и репродукция. — 2011. — Т. 5. — № 4. — С. 27–36. [Neimark AI, Razdorskaya MV. Topical problems in urogynaecology. Urinary incontinence in women (lecture). Akusherstvo, ginekologiya i reproduktsiya. 2011;5(4):27-36. (In Russ.)]
  • Пушкарь Д.Ю., Щавелева О.Б. Диагностика и результаты лечения смешанных форм недержания мочи у женщин // Урология. — 2005. — № 3. — С. 22–25. [Pushkar DY, Schaveleva ОВ. Mixed forms of urinary incontinence in women: diagnosis and treatment. Urologiia. 2005;(3):22-25. (In Russ.)]
  • Hampel C, Wienhold D, Benken N, et al. Prevalence and natural history of female incontinence. Eur Urol. 1997;32(Suppl 2):3-12.
  • Rose A, Thimme A, Halfar C, et al. Severity of urinary incontinence of nursing home residents correlates with malnutrition, dementia and loss of mobility. Urol Int. 2013;91(2):165-169. doi: 10.1159/000348344.
  • Turan C, Zorlu CG, Ekin M, et al. Urinary incontinence in women of reproductive age. Gynecol Obstet Invest. 1996;41(2):132-134. doi: 10.1159/000292059.
  • Jonas U. Introduction and conclusions. Eur Urol. 2005;4(suppl 1):1-4.
  • Осипова Н.А., Гулиев Б.Г., Ниаури Д.А., Гзгзян А.М. Осмо регулирующая функция почек при различных типах недержания мочи у женщин // Экспериментальная и клиническая урология. — 2016. — № 3. — C. 144–149. [Osipova NA, Guliev BG, Niauri DA, Gzgzyan AM. The osmo regulatory function of kidneys in women with different types of urinary incontinence. Experimental & Clinical Urology. 2016;(3):144-149. (In Russ.)]
  • Осипова Н.А., Ниуари Д.А., Гзгзян А.М. Ионорегулирующая функция почек при различных типах недержания мочи у женщин // Журнал акушерства и женских болезней. — 2016. — № 2. — C. 44–53. [Osipova NA, Niauri DA, Gzgzyan AM. Renal ionoregulation function in incontinent women. Journal of Obstetrics and Women’s Diseases. 2016;(2):44-53. (In Russ.)]. doi: 10.17816/JOWD65244-53.
  • De Rouffignac C. Multihormonal regulation of nephron epithelia: achieved through combinational mode? Am J Physiol. 1995;269(4 Pt 2):R739-748. doi: 10.1152/ajpregu.1995.269.4.R739.
  • Осипова Н.А., Ниаури Д.А., Гзгзян А.М. Патогенетическое обоснование возможности применения антидиуретического гормона при недержании мочи у женщин // Журнал акушерства и женских болезней. — 2017. — Т. 66. — № 4. — С. 68–78. [Osipova NA, Niauri DA, Gzgzyan AM. Pathogenetic justification of possibility of antidiuretic hormone use in incontinent women. Journal of Obstetrics and Women’s Diseases. 2017;66(4):68-78. (In Russ.)]. doi: 10.17816/JOWD66468-78.
  • Осипова Н.А., Ниаури Д.А., Гзгзян А.М. Опыт применения ингибитора циклооксигеназы для коррекции избы точного мочеобразования при недержании мочи у женщин // Журнал акушерства и женских болезней. — 2018. — Т. 67. — № 1. — С. 47–57. [Osipova NA, Niauri DA, Gzgzyan AM. Experience of cyclooxygenase inhibitor use for correction of urine overproduction in incontinent women. Journal of Obstetrics and Women’s Diseases. 2018;67(1):47-57. (In Russ.)]. doi: 10.17816/JOWD67147-57.
  • van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):179-183. doi: 10.1002/nau.10053.
  • Борисов И.А., Перов Ю.Л. Старческая почка // Нефрология / Под ред. И.Е. Тареевой. — М.: Медицина, 2001. — C. 509–525. [Borisov IA, Perov YL. Old kidney. In: Nephro logy. Ed by I.E. Tareeva. Moscow: Meditsina; 2001. P. 509-525. (In Russ.)]
  • Тюзиков И.А., Греков Е.А., Апетов С.С., и др. Ноктурия: современные гендерные аспекты эпидемиологии, патогенеза и диагностики // Экспериментальная и клиническая урология. — 2013. — № 3. — C. 113–122. [Tyuzikov IA, Grekov ЕА, Аpetov SS, et al. Nocturia: modern gender aspects of epydemiology, pathogenesis and diagnostics. Experimental & clinical urology. 2013;(3):113-122. (In Russ.)]
  • Jerez-Roig J, Santos MM, Souza DL, et al. Prevalence of urinary incontinence and associated factors in nursing home residents. Neurourol Urodyn. 2016;35(1):102-107. doi: 10.1002/nau.22675.
  • Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the international continence society. Am J Obstet Gynecol. 2002;187(1):116-126. doi: 10.1067/mob.2002.125704.
  • Мазо Е.Б. Медикаментозное лечение гиперактивного мочевого пузыря // РМЖ. — 2004. — T. 12. — № 8. — C. 522–526. [Mazo EB. Drug treatment of a hyperactive bladder. Russkii meditsinskii zhurnal. 2004;12(8):522-526. (In Russ.)]
  • Bissada NK, Finkbeiner AE. Urologic manifestations of drug therapy. Urol Clin North Am. 1988;15(4):725-736.
  • Sellers DJ, Chapple CR, Chess-Williams R. Potential therapeutic targets for treatment of the overactive bladder. World J Urol. 2001;19(5):307-311. doi: 10.1007/pl00007102.
  • Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs. 2005;10(1):65-83. doi: 10.1517/13543784.10.1.65.
  • Han YK, Lee WK, Lee SH, et al. Effect of Desmopressin with Anticholinergics in Female Patients with Over active Bladder. Korean J Urol. 2011;52(6):396. doi: 10.4111/kju.2011.52.6.396.
  • Hilton P, Stanton SL. The Use of Desmopressin (DDAVP) in Nocturna Urinary Frequency in the Female. Br J Urol. 1982;54(3):252-255. doi: 10.1111/j.1464-410X.1982.tb06969.x.
  • Jeong JY, Kim SJ, Cho HJ, et al. Influence of type of nocturia and lower urinary tract symptoms on therapeutic outcome in women treated with desmopressin. Korean J Urol. 2013;54(2):95-99. doi: 10.4111/kju.2013.54.2.95.
  • Lee HW, Choo MS, Lee JG, et al. Desmopressin is an effective treatment for mixed nocturia with nocturnal polyuria and decreased nocturnal bladder capacity. J Korean Med Sci. 2010;25(12):1792-1797. doi: 10.3346/jkms.2010.25.12.1792.
  • Mun JH, Kim SO, Yu HS, et al. Effects of desmopressin for the treatment of nocturnal polyuria in elderly wo men: impact on related sleep quality. Can Urol Assoc J. 2015;9(11-12):E770-774. doi: 10.5489/cuaj.3097.
  • Robinson D, Cardozo L, Akeson M, et al. Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int. 2004;93(7):996-1000. doi: 10.1111/j.1464-410X.2004.04768.x.
  • Тюзиков И.А., Калиниченко С.Ю., Ворслов Л.О., Тишова Ю.А. Дефицит вазопрессина как причина ноктурии и гормонально-метаболических нарушений у мужчин. Роль десмопрессина в их коррекции // Эффективная фармакотерапия. — 2015. — № 27. — C. 26–37. [Tyuzikov IA, Kalinichenko SY, Vorslov LO, Tishova YA. Vasopressin Deficiency as a Cause of Nocturia and Hormonal-Metabolic Disorders in Men. A Role of Desmopressin in Their Correction. Effektivnaya farmakoterapiya. 2015;(27):26-37. (In Russ.)]
  • Nørgaard JP, Pedersen EB, Djurhuus JC. Diurnal anti-diure tic-hormone levels in enuretics. J Urol. 1985;134(5):1029-1031.
  • Rittig S, Knudsen UB, Norgaard JP, et al. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol Renal Physiol. 1989;256(4):F664-F671. doi: 10.1152/ajprenal.1989.256.4.F664.
  • Осипова Н.А., Ниаури Д.А., Зиятдинова Г.М. Суточный ритм мочеобразования и мочеотделения при недержании мочи у женщин // Гинекология. — 2015. — Т. 17. — № 2. — C. 74–76. [Osipova NA, Niaury DA, Ziyatdinova GM. The circadian rhythm of urine formation in incontinent women. Gynecology. 2015;17(2):74-76. (In Russ.)]
  • Иванова Л.H. Вазопрессин: клеточные и молекулярные аспекты его антидиуретического действия // Вестник Российской академии медицинских наук. — 1999. — № 3. — С. 40–45. [Ivanova LN. Vasopressin: cellular and molecular aspects of its antidiuretic effect. Annals of the Russian Academy of Medical Sciences. 1999;(3):40-45. (In Russ.)]
  • Sabolić I, Brown D. Water transport in renal tubules is mediated by aquaporins. Clin Investig. 1994;72(9):698-700. doi: 10.1007/bf00212993.
  • Наточин Ю.В. Физиология водно-солевого обмена и почки. — СПб., 1993. [Natochin YV. Physiology of water-salt metabolism and kidneys. Saint Petersburg; 1993. (In Russ.)]
  • Aarab L, Siaume-Perez S, Chabardes D. Cell-specific coupling of PGE2 to different transduction pathways in arginine vasopressin- and glucagon-sensitive segments of the rat renal tubule. Br J Pharmacol. 1999;126(4):1041-1049. doi: 10.1038/sj.bjp.0702390.
  • Гончаревская О.А., Наточин Ю.В. Простагландин Е2 угне тает реабсорбцию магния в начальном отделе дистального отдела нефрона тритона // Доклады РАН. — 1994. — Т. 337. — № 1. — С. 125–127. [Goncharevskaja OA, Natochin YV. Prostaglandin E 2 inhibits the reabsorption of magnesium in the initial section of the distal nephron nephritis. Doklady RAN. 1994;337(1):125-127. (In Russ.)]
  • Cho KJ, Kim HS, Koh JS, Kim JC. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics. Int Urogynecol J. 2013;24(2):325-330. doi: 10.1007/s00192-012-1854-4.
  • Kim JC, Park EY, Seo SI, et al. Nerve Growth Factor and Prostaglandins in the Urine of Female Patients With Overactive Bladder. J Urol. 2006;175(5):1773-1776. doi: 10.1016/s0022-5347(05)00992-4.
  • Marentette JO, Hurst RE, McHowat J. Impaired Expression of Prostaglandin E2 (PGE2) Synthesis and Degradation Enzymes during Differentiation of Immortalized Urothelial Cells from Patients with Interstitial Cystitis/Painful Bladder Syndrome. PLoS One. 2015;10(6):e0129466. doi: 10.1371/journal.pone.0129466.
  • Danon A, Zenser TV, Thomasson DL, Davis BB. Eicosanoid synthesis by cultured human urothelial cells: potential role in bladder cancer. Cancer Res. 1986;46(11):5676-5681.
  • Wong Y-HH, Zenser TV, Davis BB. Regulation of dog urothelial cell arachidonic acid release and prostaglandin E2 synthesis. Carcinogenesis. 1989;10(9):1621-1627. doi: 10.1093/carcin/10.9.1621.
  • Delaere KP, Debruyne FM, Moonen WA. The use of indomethacin in the treatment of idiopathic bladder instability. Urol Int. 1981;36(2):124-127. doi: 10.1159/000280402.
  • Sprem M, Milicic D, Oreskovic S, et al. Intravesically admi nistered ketoprofen in treatment of detrusor instability: cross-over study. Croat Med J. 2000;41(4):423-427.
  • Takagi-Matsumoto H, Ng B, Tsukimi Y, Tajimi M. Effects of NSAIDs on Bladder Function in Normal and Cystitis Rats: a Comparison Study of Aspirin, Indomethacin, and Ketoprofen. J Pharmacol Sci. 2004;95(4):458-465. doi: 10.1254/jphs.FP0040098.
  • Tanaka I, Nagase K, Tanase K, et al. Improvement in neurogenic detrusor overactivity by peripheral C fiber’s suppression with cyclooxygenase inhibitors. J Urol. 2010;183(2):786-792. doi: 10.1016/j.juro.2009.09.071.
  • Iwasaki H, Koyama Y, Tanaka Y, et al. Modulation by desmopressin of neuronal activity in brainstem micturition center. Urology. 2004;63(5):994-998. doi: 10.1016/j.urology.2003.11.036.

Views

Abstract - 20

PDF (Russian) - 14

PlumX


Copyright (c) 2018 Osipova N.A., Niauri D.A., Gzgzyan A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.